NCT04830462View on ClinicalTrials.gov

Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation

PHASE4CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 15, 2021

Primary Completion Date

May 1, 2023

Study Completion Date

May 1, 2023

Conditions
Latent TuberculosisDiabetes Mellitus, Type 2
Interventions
DRUG

Rifampicin 300 Mg Oral Capsule

Rifampicin 600 mg orally once daily for 4 months

DRUG

Isoniazid 300 Mg ORAL TABLET

Isoniazid 300 mg daily for 6 months

Trial Locations (1)

Unknown

Herlev-Gentofte Hospital, Copenhagen

All Listed Sponsors
lead

Herlev and Gentofte Hospital

OTHER